Arbutus Biopharma
ABUS
50 hedge funds and large institutions have $91.9M invested in Arbutus Biopharma in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 21 reducing their positions, and 7 closing their positions.
54% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $683K
2% less funds holding
Funds holding: 51 → 50 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
28.77% less ownership
Funds ownership: 62.15% → 33.37% (-29%)
43% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 21
47% less capital invested
Capital invested by funds: $173M → $91.9M (-$80.9M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$7.07M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$1.54M |
| 3 |
Goldman Sachs
New York
|
+$276K |
| 4 |
JP Morgan Chase
New York
|
+$236K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$191K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$80.9M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.62M |
| 3 |
Renaissance Technologies
New York
|
-$842K |
| 4 |
Morgan Stanley
New York
|
-$607K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$592K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$101K | -19,099 | Closed |
|
|
TSS
52
Two Sigma Securities
New York
| – | -$57K | -11,294 | Closed |
|
|
VF
53
Virtu Financial
New York
| – | -$57K | -11,287 | Closed |
|
54
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$9K | -1,792 | Closed |
|
|
ML
55
McAdam LLC
Philadelphia,
Pennsylvania
| – | +$53 | +10 | New |
|
ABUS Hedge Fund Activity: Q1 2018 in Review
50 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2018, worth a combined $91.9M — down 47% from $173M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ABUS and 6 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 12 added.
The largest buyer was Foresite Capital Management IV, adding an estimated $7.07M. The largest seller was QVT Financial, exiting entirely with an estimated $80.9M sold.
- 50 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2018, down from 51 in Q4 2017.
- Funds reported $91.9M of Arbutus Biopharma stock for Q1 2018, down 47% quarter-over-quarter.
- 6 funds opened new Arbutus Biopharma positions in Q1 2018 and 7 closed out, a net change of -1 holder.
- The largest Arbutus Biopharma buyer in Q1 2018 was Foresite Capital Management IV, an estimated $7.07M added.
- The largest Arbutus Biopharma seller in Q1 2018 was QVT Financial, an estimated $80.9M sold.
Based on aggregated 13F filings for Q1 2018.